MIC1/GDF15 as a Bone Metastatic Disease Biomarker
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F17%3A10365085" target="_blank" >RIV/00216208:11140/17:10365085 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00669806:_____/17:10365085
Výsledek na webu
<a href="http://dx.doi.org/10.21873/anticanres.11477" target="_blank" >http://dx.doi.org/10.21873/anticanres.11477</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.11477" target="_blank" >10.21873/anticanres.11477</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
MIC1/GDF15 as a Bone Metastatic Disease Biomarker
Popis výsledku v původním jazyce
Aim: The aim of the study was to evaluate MIC1/GDF15 as a biomarker in the monitoring of bone metastases occurrence. Patients and Methods: The assessed group included patients diagnosed with: prostate cancer, breast cancer, lung cancer and colorectal cancer. Patients were divided into two groups based on the scintigraphy of the occurrence of bone metastases. Group 0 contained 55 patients without bone metastases, that served as the control group. Group 1 contained 75 patients with bone metastases. Results: Higher levels ( p<0.0001) of MIC1/GDF15 were found in group 1 (with bone metastases) compared to the group 0. Receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) 0.87. At the point of 90% specificity we found a 65% sensitivity and cut-off value of 1.48 ng/ml. Conclusion: Circulating MIC1/GDF15 is a powerful biomarker for bone metastatic disease but insufficient sensitivity calls for further studies incorporating combinations with other novel or routine markers.
Název v anglickém jazyce
MIC1/GDF15 as a Bone Metastatic Disease Biomarker
Popis výsledku anglicky
Aim: The aim of the study was to evaluate MIC1/GDF15 as a biomarker in the monitoring of bone metastases occurrence. Patients and Methods: The assessed group included patients diagnosed with: prostate cancer, breast cancer, lung cancer and colorectal cancer. Patients were divided into two groups based on the scintigraphy of the occurrence of bone metastases. Group 0 contained 55 patients without bone metastases, that served as the control group. Group 1 contained 75 patients with bone metastases. Results: Higher levels ( p<0.0001) of MIC1/GDF15 were found in group 1 (with bone metastases) compared to the group 0. Receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) 0.87. At the point of 90% specificity we found a 65% sensitivity and cut-off value of 1.48 ng/ml. Conclusion: Circulating MIC1/GDF15 is a powerful biomarker for bone metastatic disease but insufficient sensitivity calls for further studies incorporating combinations with other novel or routine markers.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
<a href="/cs/project/NT13655" target="_blank" >NT13655: Biomarkery kostní metastatické nemoci</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Svazek periodika
37
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
5
Strana od-do
1501-1505
Kód UT WoS článku
000397129600074
EID výsledku v databázi Scopus
2-s2.0-85015820095